EP Patent

EP3110449B1 — Medical use of a dpp-4 inhibitor

Assigned to Boehringer Ingelheim International GmbH · Expires 2023-06-28 · 3y expired

What this patent protects

Patent listed against Tradjenta.

Drugs covered by this patent

Patent Metadata

Patent number
EP3110449B1
Jurisdiction
EP
Classification
—
Expires
2023-06-28
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.